OTCQB:CYDY - OTCQB:GNBT - OTCQB:ISBG - OTCQX:WDDMF - 24/7 Market News

Venture Breakfast Bits, by 24/7 Market News

2018-11-29T09:32:14+00:00 Nov. 29, 2018 9:31AM EST|

Venture Market News for November 29, 2018

  • Generex Biotechnology Expands Medical Device & Wound Care Portfolio with Acquisition of Regentys Corporation

Generex Biotechnology Corporation (OTCMKTS:GNBT) is pleased to announce that the company has signed a Binding Letter of Intent to acquire 51% of Regentys Corporation, a regenerative medicine company focused on developing treatments for patients with gastrointestinal (GI) disorders. The company’s first product, Regentys Extra-Cellular Matrix Hydrogel, is a first-in-class, non-pharmacologic, non-surgical treatment option for patients suffering from Ulcerative Colitis. Regentys has received guidance from FDA that the treatment can be approved through the FDA Office of Device Evaluation as a 510K de novo application, and the company will initiate the clinical studies necessary to obtain that approval by Q4 2019. Generex made an initial payment of $400,000 on November 28, 2018, to secure the agreement and the company is in the process of completing the legal documents with a plan to close the transaction in the coming weeks.

Full press release

  • CytoDyn’s Prostate Cancer Prognostic Test Demonstrates Substantial Added Value to Gleason Score in Predicting Patient Outcomes

VANCOUVER, Washington, Nov. 29, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) announces that results from a recent clinical study showed that CytoDyn’s PCaTest provides substantial additive discriminative value for predicting outcomes of patients diagnosed with prostate cancer compared to the Gleason score, the current standard for prostate cancer diagnosis. The positive clinical data from two groups totaling 218 patients and followed for 10 years adds to three prior clinical studies conducted in more than 350 patients that demonstrated a high predictive value for CytoDyn’s PCaTest in determining outcome of men diagnosed with prostate cancer. The new findings support the Company’s strategy for seeking U.S. Food and Drug Administration (FDA) approval for the PCaTest.

Full press release

  • WeedMD Reports Third Quarter 2018 Financial Results

Increased Revenue by 461% Year-Over-Year Prior to Opening of Canada’s Adult-Use Market

Experienced Leadership Team in Place to Navigate Rapid Expansion Phase and Accretive Business Development Initiatives

Secured Sales Licence for State-of-the-Art Hybrid Greenhouse in Strathroy, Ontario, with Fully-Funded Path to 500,000 Square Feet of High-Quality, Cost-Effective Cannabis Cultivation

TORONTO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, is pleased to report its financial results for the three and nine months ended September 30, 2018. 

Full press release

  • ISBG Issues Corporate Update Following Major Developments

LAS VEGAS, NV, Nov. 29, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- International Spirits and Beverage Group Inc. (OTCQB:ISBG) (“ISBG” or the “Company”), a top-tier brand incubator in the Global Wine & Spirits and CBD-Infused Products markets, presents the following corporate update in the wake of several major developments that may be relevant to current and prospective ISBG investors seeking to understand the operational and strategic context for the Company.

Full press release

Connect with 24/7 Market News on social media

https://twitter.com/247MarketNewsHQ

https://www.facebook.com/247MarketNewsHQ/

About 24/7 Market News

As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information.  24/7 MN provides comprehensive corporate communications resources and tools to engage the investment community.

DISCLAIMER:

24/7 Market News (24/7MN) is a third party publisher and news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7MN's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.

The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable. 24/7MN makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice.   24/7MN and/or its affiliates are not responsible for any gains or losses that result from the opinions expressed and are not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.

For further information on 24/7 Market News, please go to www.247marketnews.com 

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan," or "planned," "will," or "should," "expected," "anticipates," "draft," "eventually," or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 24/7MN undertakes no obligation to update such statements

CONTACT:

24/7 Market News

Editor@247marketnews.comTop of Form

Send this to a friend

Hi, this may be interesting you: Kraig Biocraft Laboratories’ New R&D Facility Extends Its Competitive Advantages and Prepares for Large Scale Production! This is the link: https://www.247marketnews.com/kraig-biocraft-laboratories-new-rd-facility-extends-its-competitive-advantages-and-prepares-for-large-scale-production/